Extreme Levels of Platelet Count in Essential Thrombocythemia: Management and Outcome, Report of Two Cases

Mohammad Abu-Tineh; Mohamed A Yassin

doi:10.1159/000507363

Extreme Levels of Platelet Count in Essential Thrombocythemia: Management and Outcome, Report of Two Cases

Case Rep Oncol. 2020 Jun 4;13(2):606-610. doi: 10.1159/000507363. eCollection 2020 May-Aug.

Authors

Mohammad Abu-Tineh¹, Mohamed A Yassin²

Affiliations

¹ Department of Medical Education, Hamad Medical Corporation, Doha, Qatar.
² National Center for Cancer Care and Research, Department of Oncology, Hematology and BMT Section, Hamad Medical Corporation, Doha, Qatar.

Abstract

Myeloproliferative neoplasms including essential thrombocythemia (ET) is usually caused by somatic mutations in multiple genes, including the JAK2 (most frequently), CALR gene, and MPL. In rare cases, the disease is caused by other mutations such as THPO or TET2 gene; however, around 10-15% with ET might have triple-negative mutations. Here we present 2 cases of ET who were asymptomatic on diagnoses, but found to have extremely high platelet counts as never reported earlier. The management and treatment plan can be a challenging step. The objective is to draw attention to the early introduction of thrombocytapheresis in the management of such patients given its notable outcomes.

Keywords: Cytoreduction; Essential thrombocythemia; Myeloproliferative neoplasm; Thrombocytapheresis.

Publication types

Case Reports